Yoshida Y, Kitamura S, Kawachi K, Taniguchi S, Kondo Y
Department of Surgery III, Nara Medical College, Kashihara, Japan.
J Heart Lung Transplant. 1994 Mar-Apr;13(2):325-31.
Clinical observations indicate that in heart-lung grafting the heart is less frequently rejected than in heart grafting alone. In addition, our results of allograft experiments indicated that the graft survival period is longer in the former (11.8 +/- 0.8 days versus 6.6 +/- 0.5 days, p < 0.05), suggesting that the simultaneous grafting of the lung in heart-lung allografts suppressed the rejection of the grafted heart. We assessed the effect of simultaneous lung xenografting, splenectomy, and FK506 treatment on the survival of the xenografted heart in a concordant model. With Wistar rats as recipients and golden hamsters as donors, cardiac survival was compared between en bloc heart-lung and heart heterotopic xenografts. The cardiac survival of heart-lung and heart xenografts was not prolonged by FK506 treatment alone but was prolonged by splenectomy. Splenectomy plus FK506 (1.0 mg/kg/day) showed suppression of antibody production and a remarkable synergistic effect in prolongation (33.2 +/- 7.4 days versus 36.8 +/- 8.1 days) in heart-lung and heart xenografts. Simultaneous lung xenografting significantly shortened the survival period of the xenografted heart in splenectomy plus FK506 (0.5 mg/kg/day) recipients (4.8 +/- 0.8 days versus 9.0 +/- 3.5 days, p < 0.05), in contrast to the prolongation of the survival period of the grafted heart in heart-lung allografting.
临床观察表明,在心肺移植中,心脏被排斥的频率低于单纯心脏移植。此外,我们的同种异体移植实验结果表明,前者的移植物存活期更长(11.8±0.8天对6.6±0.5天,p<0.05),这表明心肺同种异体移植中同时移植肺抑制了移植心脏的排斥反应。我们在一个协调性模型中评估了同时进行肺异种移植、脾切除术和FK506治疗对异种移植心脏存活的影响。以Wistar大鼠为受体,金黄地鼠为供体,比较了整块心肺和心脏异位异种移植的心脏存活情况。单独使用FK506治疗并不能延长心肺和心脏异种移植物的心脏存活期,但脾切除术可以延长。脾切除术加FK506(1.0毫克/千克/天)在心肺和心脏异种移植物中显示出抑制抗体产生的作用以及在延长存活期方面有显著的协同效应(33.2±7.4天对36.8±8.1天)。与心肺同种异体移植中移植心脏存活期延长相反,在脾切除术加FK506(0.5毫克/千克/天)的受体中,同时进行肺异种移植显著缩短了异种移植心脏的存活期(4.8±0.8天对9.0±3.5天,p<0.05)。